SOLVAY S.A. having its headquarters situated at Brussels has been ranked amongst 40 major pharmaceutical companies in the world. The company is strongly placed in its specialized therapeutic sectors. Solvay has drastically reformed within recent past duly paying attention on compatibility, spear-heading and remarkable value-added activities intended to continuous and lucrative development led by the obsession for modernization.

Solvay group operates in various sectors like pharmaceuticals, chemicals and plastics and has been able to generate EUR of 9.4 billion by sales during 2006 through over 400 units spanning in more than 50 countries of the world. Nearly 29,000 people’s workforce has been applying their skills regularly to cater to the demands of almost 160,000 customers of the group.

The major product range of the company comprising of various medical segments include:

·         TEVETEN & OMACOR for treating the Cardiometabolics related problems

·         DUODOPA used in treating the neuroscience linked disorders

·         INFLUVAC used as the most effective flu vaccines

·         CREON widely prescribed as the pancreatic enzymes

·         DUPHALAC used for treating the gastroenterology disorders and

·         ANDROGEL for various applications in both women and men health

Research and development involvements are classified specifically between such diverse fields. In the first two categories mentioned above, the company is committed to maintain its investments by all means including research & development and marketing the products through out the global markets.  

Vaccines for influenza and enzymes for pancreatic needs has been the point of aimed investments which incorporates both R&D and licensing agreements. Whereas gastroenterology and both women’s and men’s health would be the downstream actions focusing greatly on marketing.